Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products ...

OPUVIZ™, a biosimilar referencing Eylea1 (aflibercept), is Samsung Bioepis and Biogen’s second ophthalmology biosimilar to be recommended for marketing authorization by the European Medicines Agency ...

Samsung Bioepis, Biogen receive positive CHMP opinion for aflibercept biosimilar, Opuviz: Incheon, Korea Monday, September 23, 2024, 12:00 Hrs [IST] Samsung Bioepis Co., Ltd., a b ...

OPUVIZ, a biosimilar referencing Eylea1 (aflibercept), is Samsung Bioepis and Biogen's second ophthalmology biosimilar to be recommended for marketing authorization by the European Medicines Agency IN ...

Dr. Lloyd Minor and Prof Sir Menelas Pangalos bring significant scientific expertise and considerable experience in medicine ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Viehbacher, Biogen President and Chief Executive Officer ... our dependence on sales from our products; uncertainty of long-term success in developing, licensing, or acquiring other product ...

The patents cover sales of Biogen products for MS that are covered by a Forward Pharma patent and have dimethyl fumarate as an active pharmaceutical ingredient. The two companies say they intend ...

Biogen will retain its commercial rights to ... The agreement gives Samsung Bioepis exclusive rights to another three products in phase 3 testing, including biosimilars of AstraZeneca/Alexion's ...

Amid declining demand for MS drugs and Spinraza, Biogen believes its new products, Leqembi for Alzheimer’s disease, Skyclarys for Friedreich’s ataxia and Zurzuvae for depression, have the ...